NCT04330066

Brief Summary

The purpose of this pilot study is to evaluate whether a decrease in endometrial thickness (compaction) prior to progesterone exposure (endogenous or exogenous) to the day before a single frozen embryo transfer has an impact on the clinical pregnancy rate with euploid embryos in exogenous hormone and modified natural thaw cycles. Information derived from this study may give insight on ways to improve pregnancy rates in cryo-thaw cycles.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
187

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 30, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 1, 2020

Completed
5 months until next milestone

Study Start

First participant enrolled

September 1, 2020

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2022

Completed
Last Updated

March 11, 2022

Status Verified

March 1, 2022

Enrollment Period

1.7 years

First QC Date

March 30, 2020

Last Update Submit

March 10, 2022

Conditions

Keywords

endometrial compactionfrozen embryo transfereuploid embryoultrasound

Outcome Measures

Primary Outcomes (1)

  • Clinical pregnancy rate

    defined as confirmation of gestational sac with fetal heart beat on ultrasound between 6 - 9 weeks gestation

    through study completion, an average of 1 year

Secondary Outcomes (3)

  • Biochemical pregnancy rate

    through study completion, an average of 1 year

  • Live birth rate

    through study completion, an average of 1 year

  • Miscarriage rate

    through study completion, an average of 1 year

Study Arms (2)

Exogenous hormone replacement thaw cycle

Participants in this group will follow Boston IVF's standard exogenous hormone replacement protocol. Participants will take Estrace 3mg twice daily by mouth for endometrial preparation. After 16-18 days of Estrace, endometrial thickness will be measured by transvaginal ultrasound but medication and ultrasounds will be continued until the endometrial lining is ≥ 7 mm. Once the final endometrial lining is ≥ 7 mm (T1), the doctor of record will start the participant the following day with intramuscular progesterone daily or intramuscular progesterone every 3 days with daily vaginal progesterone. Frozen embryo transfers would occur on the sixth day of progesterone.

Diagnostic Test: Abdominal ultrasound measurement of the endometrial lining

Natural thaw cycle

Participants in this group will follow Boston IVF's standard natural thaw cycle protocol. Participants will be coming for blood and transvaginal ultrasound monitoring around day 11 of the participants cycle. Once the participant has a final measurement of the endometrial lining ≥ 7 mm (T1), a 17mm ovarian follicle, and a progesterone \< 1.2 ng/mL, the doctor of record will schedule the patient to receive a trigger injection to induce ovulation followed by an embryo transfer 6-7 days later. Participants may be started on vaginal progesterone 4 days after the trigger injection for added supplementation per the doctor of record.

Diagnostic Test: Abdominal ultrasound measurement of the endometrial lining

Interventions

On the day of the participants frozen embryo transfer, an endometrial thickness measurement (T2) will obtained from an abdominal ultrasound during the embryo transfer.

Exogenous hormone replacement thaw cycleNatural thaw cycle

Eligibility Criteria

Age18 Years - 44 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Participants that are having a single frozen embryo transfer with a euploid embryo.

You may qualify if:

  • Single euploid frozen embryo transfer
  • ≥ 7 mm endometrial lining on transvaginal ultrasound
  • st or 2nd frozen embryo transfer

You may not qualify if:

  • Obesity with body mass index \> 40
  • Underweight with body mass index \< 18.5
  • Utilization of a gestational carrier
  • History of recurrent pregnancy loss (≥ 2 spontaneous abortions)
  • Uterine factors (history of uterine adhesions, uterine surgery, fibroids, polyps)
  • History of an endometrial receptivity assay (ERA) biopsy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Boston IVF

Boston, Massachusetts, 02109, United States

Location

Related Publications (1)

  • Shah JS, Vaughan DA, Dodge LE, Leung A, Korkidakis A, Sakkas D, Ryley DA, Penzias AS, Toth TL. Endometrial compaction does not predict live birth in single euploid frozen embryo transfers: a prospective study. Hum Reprod. 2022 May 3;37(5):980-987. doi: 10.1093/humrep/deac060.

MeSH Terms

Conditions

Infertility, Female

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesInfertility

Study Officials

  • Alan Penzias, MD

    Boston IVF

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 30, 2020

First Posted

April 1, 2020

Study Start

September 1, 2020

Primary Completion

May 30, 2022

Study Completion

June 30, 2022

Last Updated

March 11, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will not share

Locations